(Adnkronos) – CHENGDU, China, March 18, 2023 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and
>>> vai all'articolo completo
